about
Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsRegulation of human hepatic drug transporter activity and expression by diesel exhaust particle extractInhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.Exploiting open data: a new era in pharmacoinformatics.Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness.Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3.Effects of Antiviral Drugs on Organic Anion Transport in Human Placental BeWo Cells.Improved large-scale prediction of growth inhibition patterns using the NCI60 cancer cell line panel.Effect of OATP-binding on the prediction of biliary excretion.Nature and uses of fluorescent dyes for drug transporter studies.ADME-Space: a new tool for medicinal chemists to explore ADME properties.Computational modeling to predict the functions and impact of drug transporters.The recent progress in proteochemometric modelling: focusing on target descriptors, cross-term descriptors and application scope.The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy.Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Benchmarking of protein descriptor sets in proteochemometric modeling (part 2): modeling performance of 13 amino acid descriptor sets.Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design?Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets.Interaction of the bioactive flavonol, icariin, with the essential human solute carrier transporters.Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.Identification of Allosteric Modulators of Metabotropic Glutamate 7 Receptor Using Proteochemometric Modeling.Interactions of the active components of Punica granatum (pomegranate) with the essential renal and hepatic human Solute Carrier transporters.Illuminating the origins of spectral properties of green fluorescent proteins via proteochemometric and molecular modeling.Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospectsGlycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3
P2860
Q28236180-5023BBCB-2086-4C61-A17F-EEA31BBC298AQ28239708-43F075FB-962C-4940-BEBC-27C8F830B697Q28390477-D665A07B-0786-44EE-BDE4-B3C47885B842Q28818842-911D5787-8AC9-45A8-AE87-F8C788CFDD1DQ30486817-87BD8007-6700-4086-953D-54955EB01E8CQ34432585-1363016F-CE2B-4F28-9B74-0D4AFCF57476Q35150765-FBCAC3F3-A6E2-4B47-9DCC-AA9B11F72FFAQ36290804-2C286D67-8909-47D7-B1FC-B8A2B93536DCQ36379132-DA007B2C-071B-4685-8EFE-101267E7A1C1Q38436729-1FAB1878-D4D8-47EB-A041-08E12A7E5A12Q38518912-D6D1C64F-F209-4EB9-957C-45DAD4046765Q38661488-09372FE3-16B7-4052-A9CD-B9BDEDFAAEB8Q38715008-C949AEC4-0550-418A-91D2-E92AE251C7BDQ38731960-0FF841C4-A9A9-44D4-BD67-214E77E64F81Q38793280-1E4C29DB-AD59-45A2-AD0B-86977D6EAD07Q38827713-5ADE32EC-DFDD-4598-A289-7786B426C9F7Q39178447-7A6ED772-1312-4151-9690-B7F3324BEA1FQ39411048-94C4EFB9-DE52-432B-B78D-3B221DF0D9D4Q39534317-AE43B93F-A0AD-4CCB-9E6D-CFC8B3AF8784Q41760025-6BD6AF06-EEDD-45C1-AEF1-A820FFE158E6Q42708245-966005B8-A9AC-49B8-BE29-0735B5E6A3B7Q43940290-C408D66E-CDCC-4B31-B715-F12C4A6CECE2Q46591319-E0496AD5-C910-43B1-92F9-CFD299907D75Q47172533-3B0A1207-EA98-4A32-AFFE-4F25CF6DE6ECQ48519109-E77EBBCD-3E98-486B-9844-E62AD223A86BQ50451269-9CA22CF7-3C97-476B-8196-70D0D49678DBQ50749129-E265D53F-DB04-4C79-9D67-6F65B0D93D36Q54152494-3DF84AE2-6C45-44A5-A4E1-12BB7BAAF79EQ57109347-49147E4D-AF5B-4976-BEB9-3E6EB26220B4
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Structure-based identification of OATP1B1/3 inhibitors.
@ast
Structure-based identification of OATP1B1/3 inhibitors.
@en
Structure-based identification of OATP1B1/3 inhibitors.
@nl
type
label
Structure-based identification of OATP1B1/3 inhibitors.
@ast
Structure-based identification of OATP1B1/3 inhibitors.
@en
Structure-based identification of OATP1B1/3 inhibitors.
@nl
prefLabel
Structure-based identification of OATP1B1/3 inhibitors.
@ast
Structure-based identification of OATP1B1/3 inhibitors.
@en
Structure-based identification of OATP1B1/3 inhibitors.
@nl
P2093
P50
P356
P1476
Structure-based identification of OATP1B1/3 inhibitors.
@en
P2093
Bruno Stieger
Pieter P Annaert
Tom De Bruyn
P304
P356
10.1124/MOL.112.084152
P577
2013-04-09T00:00:00Z